9:00 am Chair’s Opening Remarks

9:10 am Industry Leader’s Fireside Chat

10:00 am Programming Translation of T Cell Therapies and Planning for Automation

  • Bruce Levine Cancer Gene Therapy & Founding Director, Clinical Cell & Vaccine Production Facility, University of Pennsylvania

10:30 am Virtual Speed Networking

DISCOVERY

Developing Safe, Controllable CAR-TCR Product

11:30 am Pharmacologic Control for Enhanced Efficacy Against Solid Tumors

  • Molly Perkins Senior Director, Cell Therapy, Obsidian Therapeutics

11:50 am Approaches to Reduce Toxicities Associated with CAR T Cell Intervention

  • John Rossi Senior Director, Translational Medicine, Kite, a Gilead Company

12:10 pm Novel CellGenix® T Cell Medium (CellGenix® TCM)

12:30 pm Live Q&A with Your Expert Speakers

Tech Slam

12:45 pm How 30+ Years of Experience Ensured Delivery of Time-Critical Cell Therapies During the COVID-19 Pandemic

  • Tim Tripp Director, Cell and Gene Therapy Operations, Be The Match BioTherapies

12:55 pm WellSky Biotherapies Lab: Software to Manage Stem and Novel Cell Therapies, Gene Therapies, and Regenerative Medicine

1:05 pm Advancing QC for Cell and Gene Therapies – From Starting Material to Product Delivery

1:15 pm Refreshment Break

Synopsis

Take this break to follow up with our expert partners and explore the demo area!

Innovative Target Identification to Define Clinically Beneficial & Safe Targets

1:45 pm TScan, a Whole Genome, Unbiased Approach to Cancer Target Discovery

2:10 pm Driving Novel Tumor Targeting with Neoantigen-directed Therapies

2:35 pm TCR-T Therapies for Solid Tumors Using Multiple Novel Targets

3:00 pm Refreshment Break

3:15 pm Data-Driven Approaches for Consistent Apheresis

  • Hassan Saleem Head of Global Apheresis Operations, bluebird bio
  • Lee Clough Tissue Operations Expert, Apheresis Operations Europe, Novartis
  • Rocky Billups Vice President, Operations, Sarah Cannon Blood Cancer Network HCA
  • Augustus Kilgore Sr. Global Training Consultant, Cell & Gene Therapy, Terumo Blood and Cell Technologies

4:15 pm Refreshment Break

Novel Construct Design to Tackle the Solid Tumor Microenvironment

4:30 pm Multi-Antigen Targeting for Diverse Cancers – Keep it Simple!

4:55 pm Co-Stimulatory Switch Receptors Imbue TCR-Ts with Improved Functional Capacities

Next Generation Gene Engineering Approaches for Enhanced Specificity

5:20 pm Implementation of Next Generation Gene Editing for Allogeneic T Cell Therapeutics

5:45 pm iPSC-derived Targeted NK Cells for Hematologic Cancer Treatment

6:10 pm Chair’s Closing Remarks

6:15 pm Post-Conference Networking

Synopsis

Follow up with those you have met online during the conference or join the open networking room to discuss the day with your colleagues.